Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MVT-100 vs Definity for Suboptimal Echocardiograms
NCT03882359Phase 2Completed
- Sponsor
- Microvascular Therapeutics
- Start
- Apr 2019
- Primary completion
- Sep 2024
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of MVT-100 (2 arms), sponsored by Microvascular Therapeutics. Primary endpoints: QT Interval, Blood Pressure and 1 more. Started Apr 2019; status: completed.
02
Drugs
MVT-100
Beyond the preview
Go deeper on NCT03882359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03882359.